MBS Digest
MBS Digest curates recent research, policy, access, and market signals for bariatric surgeons and obesity medicine specialists. This issue keeps the focus on practical program decisions: how to govern patient-facing AI, how to reduce supplement nonadherence, how to frame concurrent hernia repair and reoperative surgery, and how to interpret a fast-moving incretin pipeline without losing the role of durable surgical care.
We welcome inquiries, tips, letters to the editor, and article ideas from the MBS community. Reach us at [email protected]. Your submissions help shape what we cover.
ChatGPT evidence is promising, but obesity programs need guardrails before patient-facing use
This review synthesized 37 studies evaluating ChatGPT in obesity-related contexts, including lifestyle counseling, nutrition, and bariatric surgery. Performance was encouraging in several narrow tasks: high accuracy was reported in 9 of 12 lifestyle and nutrition studies and 5 of 10 bariatric surgery studies when compared with expert or guideline standards. Confidence in the evidence remains limited, with only 10 studies rated as high confidence. The signal is real, but the evidence base is still early and uneven.
For bariatric programs, the immediate question is not whether patients will use AI tools. They already will. The operational issue is whether programs can define safe boundaries: education versus advice, escalation to clinicians, privacy, bias monitoring, and consistency with local pathways. ChatGPT may help with reinforcement and navigation, but it should not become an unsupervised substitute for clinical judgment, risk stratification, or longitudinal follow-up.
AI can support patient education and program navigation, but obesity care needs governance before automation. Scope limits, bias review, privacy protections, and clinician escalation pathways should come before broad deployment.
Supplement formulation may matter as much as counseling after bariatric surgery
This cross-sectional survey included 110 adults at least one month after metabolic and bariatric surgery in Mumbai. Most had undergone Roux-en-Y gastric bypass, and 70% preferred swallowable supplements over chewables. Discontinuation was common: 41% of respondents had stopped supplements at some point. Patients using swallowable products reported higher satisfaction, 68% versus 30%, and higher current use, 93.5% versus 75.8%.
The findings challenge a familiar assumption in post-MBS care. Chewables are often presented as the easier option, but taste, pill burden, cost, availability, and patient preference can drive adherence more than the format chosen by the program. For surgeons and dietitians, the practical move is to treat supplementation like any other chronic therapy: ask what the patient will actually take, identify barriers early, and adjust formulation before deficiency appears.
Swallowable supplements were preferred by most surveyed patients and were associated with higher satisfaction and current use. Adherence counseling should include formulation choice, not just reminders.
Concurrent hernia repair during bariatric surgery carries measurable short-term risk
This 2023 MBSAQIP analysis examined 180,544 bariatric cases, including 2,292 patients who underwent concurrent abdominal wall hernia repair. Concurrent repair was uncommon, about 1.3% of cases, and most hernias were primary, reducible, and small to medium in size. Compared with bariatric surgery alone, combined cases had higher reoperation, readmission, serious complication, and mortality rates. Predictors of serious complications included medium hernia size, older age, VTE history, and Roux-en-Y gastric bypass.
This is not an argument for blanket avoidance. It is an argument for being explicit about risk. A symptomatic or incarceration-prone hernia may still justify repair at the index operation, while an incidental or low-risk defect may be better staged. Medium defects, bypass cases, and patients with thromboembolic history deserve a more deliberate consent discussion and a plan that accounts for mesh strategy, operative time, and postoperative monitoring.
Concurrent repair should be individualized rather than reflexive. MBSAQIP data support shared decision-making that separates small incidental defects from higher-risk medium hernias and more complex bypass cases.
Reoperative bariatric surgery is now a routine sleeve-era practice reality
This MBSAQIP study reviewed 828,481 bariatric operations from 2020 through 2023 and identified 90,410 elective reoperations, representing 10.9% of total volume. Sleeve-related reoperations dominated the dataset. Among sleeve reoperations, conversion to Roux-en-Y gastric bypass accounted for 80.9%, while DS/SADI accounted for 11%. The leading indications were weight recurrence or nonresponse, 53.7%, and GERD, 32.2%.
The practice implication is straightforward. Revision is no longer a niche activity at high-volume referral centers. It is part of contemporary bariatric surgery, and counseling should move beyond the generic phrase "revision risk." Programs need objective indication assessment, reflux workup when appropriate, procedure-specific risk counseling, and long-term expectations that distinguish GERD conversion, weight recurrence, and nonresponse.
Elective reoperations accounted for about one in nine MBSAQIP bariatric cases from 2020 to 2023. Sleeve-era GERD and weight recurrence are now core drivers of modern reoperative practice.
Retatrutide moves triple-agonist therapy into surgery-adjacent efficacy territory
Lilly reported additional Phase 3 data for retatrutide, an investigational once-weekly GIP, GLP-1, and glucagon receptor agonist. In TRIUMPH-1, the 12 mg dose produced mean weight loss of 28.3% at 80 weeks, with 65.3% of participants moving below a BMI of 30 and 33.3% below a BMI of 25. TRANSCEND-T2D-1 showed A1C reductions up to 2.0% and weight loss up to 16.8% at 40 weeks in people with type 2 diabetes. Lilly also reported improvement in knee osteoarthritis pain and obstructive sleep apnea measures.
These are not routine GLP-1 incremental data. If confirmed in regulatory review and real-world use, retatrutide would create a larger group of patients who arrive at surgical consultation after substantial medication-associated weight loss, or who use medication as part of staged metabolic care. For bariatric surgeons, that makes integrated pathways more important, not less important: medication response, nonresponse, intolerance, reflux, anatomic disease, and durability all need a shared care model.
Retatrutide remains investigational, but the magnitude of trial weight loss changes referral conversations. Programs should prepare for more patients moving between medication-first, surgery-first, and combined strategies.
CagriSema reinforces the shift from GLP-1 monotherapy to layered gut-hormone treatment
Novo Nordisk presented Phase 3 REIMAGINE 1 through 3 data for CagriSema, a fixed-dose combination of cagrilintide and semaglutide. In REIMAGINE 1, the 2.4 mg/2.4 mg dose reduced A1C by 1.8 percentage points and body weight by 13.8% at 40 weeks. In REIMAGINE 2, weight loss reached 14.2% at 68 weeks with A1C reduction up to 1.91 percentage points. The trials position amylin plus GLP-1 signaling as a serious next step in type 2 diabetes and obesity pharmacotherapy.
The practical clinical message is that medication therapy is becoming more mechanism-specific. Surgeons will increasingly see patients exposed to multiple incretin or amylin-based regimens before referral, and some will present after a plateau, adverse effects, or weight recurrence after discontinuation. A good bariatric evaluation will need to document medication history with the same care we already apply to prior operations, reflux testing, diabetes duration, and nutritional risk.
CagriSema produced clinically meaningful A1C and weight reductions across several type 2 diabetes settings. The pipeline is moving toward layered hormonal therapy rather than GLP-1 monotherapy alone.
Orforglipron strengthens the case for oral incretin therapy in type 2 diabetes
Lilly reported results from three Phase 3 ACHIEVE trials of orforglipron, a once-daily oral small-molecule GLP-1 receptor agonist branded as Foundayo in the release. In ACHIEVE-3, the 17.2 mg dose lowered A1C by 2.2% and body weight by 9.2% at 52 weeks, compared with 1.4% and 5.3% for oral semaglutide 14 mg. Lilly also reported positive results versus dapagliflozin in ACHIEVE-2 and placebo added to insulin glargine in ACHIEVE-5. Submission for type 2 diabetes was planned by the end of the second quarter of 2026.
Oral therapy may reduce friction for patients who decline injections, struggle with supplies, or already manage complex medication routines. It does not eliminate adherence challenges, payer restrictions, or the need for durable obesity treatment planning. For MBS practices, an oral GLP-1 option may become part of preoperative optimization, post-surgical weight recurrence management, or nonsurgical treatment for patients who are not ready for an operation.
Oral incretin therapy could broaden access and persistence, but programs should avoid treating route of administration as a solution by itself. Durability, tolerability, cost, and sequencing with surgery remain the clinical questions.
Zenagamtide adds another amylin-based signal to the obesity and diabetes pipeline
Novo Nordisk reported Phase 2 dose-finding data for zenagamtide, also known as amycretin, a unimolecular GLP-1 and amylin receptor agonist. The study enrolled 262 adults with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor. Across tested doses, zenagamtide produced statistically significant A1C reductions, with the highest dose showing A1C reduction up to 1.71 percentage points and body weight reduction up to 14.6% at 36 weeks. Novo stated that Phase 3 development in type 2 diabetes is planned for the second half of 2026.
The point for bariatric clinicians is not to memorize every pipeline asset. The point is to recognize the direction of travel. Amylin biology is becoming central to next-generation obesity medicine, and future patients may cycle through agents with different appetite, glycemic, and tolerability profiles. Surgical programs that build medication-aware follow-up will be better positioned than programs that view pharmacotherapy as external to bariatric care.
Zenagamtide is still Phase 2, and durability after discontinuation remains an open question. The early data add to the case that amylin-based therapy will shape future obesity treatment algorithms.
Oral GLP-1 competition and Medicare access may shift the bottleneck from demand to coordination
CNBC reported that Novo Nordisk and Lilly used the ADA meeting to frame competing oral GLP-1 obesity strategies just as Medicare access is scheduled to change. CMS separately announced that eligible Medicare beneficiaries with Part D coverage may access certain GLP-1 medications for $50 per month beginning July 1, 2026, under a time-limited Medicare GLP-1 Bridge demonstration. The story is not only about pills versus injections. It is about coverage, awareness, pharmacy operations, prior authorization behavior, and whether a broader Medicare population can actually obtain treatment.
For bariatric programs, improved medication access can change patient flow in both directions. Some patients may seek pharmacotherapy before considering surgery, while others may use medication for preoperative optimization or post-surgical weight recurrence. Programs should expect more questions about sequencing, medication failure, intolerance, and whether improved access reduces or delays surgical referral. The answer will likely depend less on enthusiasm and more on local coverage rules and integrated follow-up.
Lower monthly Medicare cost sharing could widen pharmacotherapy access, but it will not remove the need for surgical programs. The likely pressure point is coordination across medication, nutrition, behavioral care, and surgery.
SELECT keeps semaglutide in a cardiometabolic frame, not just a weight-loss frame
ADA Meeting News previewed additional SELECT analyses examining semaglutide effects beyond the previously reported 20% reduction in major cardiovascular events among people with overweight or obesity, established cardiovascular disease, and no diabetes. The planned analyses focus on glycemia, prediabetes progression and regression, inflammation, heart failure, and anthropometric outcomes across a trial population of more than 17,000 participants. SELECT was not designed primarily as a diabetes prevention trial, but the dataset provides a large view of cardiometabolic risk change in a high-risk population.
This matters to MBS programs because the public conversation often reduces obesity treatment to pounds lost. Cardiovascular risk, diabetes trajectory, liver disease, sleep apnea, reflux, joint disease, and functional status are the outcomes patients and payers increasingly use to judge value. Bariatric surgery has long made its strongest case when framed as metabolic risk modification. GLP-1 outcome data should push the field toward better comparative and complementary outcome reporting, not a narrow procedure-versus-drug debate.
SELECT reinforces that obesity therapy is cardiometabolic care. Bariatric programs should keep outcomes language broad: diabetes trajectory, cardiovascular risk, sleep apnea, joint disease, quality of life, and durability.
AMA backs obesity coverage parity across surgery, medication, nutrition, and behavioral care
Final House action was confirmed for AMA Resolution 710, Parity in Access to Evidence-Based Obesity Treatment. The resolution frames obesity coverage as chronic-disease care and supports access to the full spectrum of evidence-based therapy, including intensive behavioral treatment, nutrition therapy, anti-obesity medications, endoscopic therapies, and metabolic and bariatric surgery. It also opposes obesity-specific exclusions, unsupported supervised weight-loss mandates, arbitrary BMI thresholds, payer-defined weight-loss targets, and treatment sequencing rules that override physician-patient decision-making.
For MBS programs, the policy value is advocacy leverage. AMA policy does not automatically change Medicare, Medicaid, employer benefit design, or commercial prior authorization rules. It does, however, gives surgeons and obesity clinicians a stronger platform when arguing that surgery, medication, nutrition, and behavioral care should not be carved into artificial silos. The most useful next step is to translate this into payer conversations, employer benefit work, and state-level advocacy.
AMA passage strengthens the parity argument for comprehensive obesity care. The practical target is payer policy that treats MBS and pharmacotherapy as evidence-based chronic-disease treatment rather than optional or sequential benefits.
Lilly and Novo used ADA to defend different parts of the obesity-treatment market
Lilly arrived at ADA with a broad obesity narrative: retatrutide for next-generation efficacy, orforglipron for oral access and type 2 diabetes, and continued positioning around Zepbound. Novo Nordisk countered with CagriSema, zenagamtide, semaglutide outcomes, and a strong oral Wegovy access story. The market signal is that the leading companies are no longer competing on one molecule or one route of administration. They are competing on portfolios that span efficacy, tolerability, cardiometabolic outcomes, and payer access.
For MBS programs, this creates a more complicated but potentially more useful landscape. Patients may arrive after several medication attempts, and payers may try to impose sequencing rules based on price rather than evidence. Surgeons should expect more pressure to document why a given patient needs surgery, medication, or both. The strongest response is not to argue against the pipeline, but to insist on individualized, durable, evidence-based treatment selection.
The obesity market is becoming a portfolio contest: injectable, oral, amylin-based, triple-agonist, and outcomes-driven. MBS programs should prepare for payer sequencing debates as much as patient demand.
CMS GLP-1 Bridge could alter volume, access, and payer strategy without settling the coverage debate
CMS announced a time-limited Medicare GLP-1 Bridge demonstration offering eligible Part D beneficiaries access to certain GLP-1 medications at $50 per month from July 1, 2026, through December 31, 2027. The announcement is a major access signal for manufacturers, pharmacies, payers, and clinical programs. It also creates a defined period in which adherence, demand, cost, outcomes, and operational burden will be watched closely.
Bariatric teams should treat this as a coverage experiment with downstream implications. If the demonstration improves access and outcomes, it may strengthen broader obesity-benefit arguments. If it produces bottlenecks, discontinuation, or payer friction, programs will need to help patients navigate realistic options. Either way, surgery remains part of the evidence-based spectrum, especially for severe obesity, reflux-driven revision, diabetes remission goals, and patients needing durable anatomic intervention.
The bridge runs from July 2026 through December 2027. Its real-world performance may influence future coverage negotiations for medication, surgery, and integrated obesity care.
Invited surgeon commentaries are forthcoming. If you are interested in contributing a perspective or editorial on a topic relevant to metabolic and bariatric surgery, please contact us at [email protected].
Kalshi: Trade every World Cup match. Who wins, who advances, who lifts the trophy. Official partner of Argentina's national team. Peer-to-peer, no house, get $10 free. Start Trading.